Debreova M, Culenova M, Smolinska V, Nicodemou A, Csobonyeiova M, Danisovic L. Rheumatoid arthritis: from synovium biology to cell-based therapy. Cytotherapy. 2022;24(4):365–75.
Article CAS PubMed Google Scholar
Rheumatoid arthritis. 2023. https://www.who.int/news-room/fact-sheets/detail/rheumatoid-arthritis.
Gupta BM, Gupta R, Kumar A, Bansal M. Rheumatoid arthritis research in India: a scientometric assessment of publications during 2007–2016. SF J Orthopedic Rheumatol 2018.
Liao KP, Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol. 2009;21(3):279.
Article PubMed PubMed Central Google Scholar
McGraw WT, Potempa J, Farley D, Travis J. Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect Immun. 1999;67(7):3248–56.
Article CAS PubMed PubMed Central Google Scholar
Lin Y-J, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4):880.
Article CAS PubMed PubMed Central Google Scholar
Anderson AS, Loeser RF. Why is osteoarthritis an age-related disease?, Best practice & research. Clin Rheumatol. 2010;24(1):15–26.
Littlejohn EA, Monrad SU. Early diagnosis and treatment of rheumatoid arthritis. Primary care: Clinics in office practice. 2018;45(2):237–55.
Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone res. 2018;6(1):15.
Article PubMed PubMed Central Google Scholar
Cojocaru M, Cohocaru IM, Chico B. New insight into the rheumatoid vasculitis. Rom J Intern Med. 2015;53(2):128–32.
Charleson K. Types of rheumatoid arthritis. 2023. https://www.verywellhealth.com/types-of-rheumatoid-arthritis-5093089#citation-7. Accessed 11/11/2023 2023.
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–72.
Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. The Lancet. 2017;389(10086):2338–48.
Watanabe R, Okano T, Gon T, Yoshida N, Fukumoto K, Yamada S, Hashimoto M. Difficult-to-treat rheumatoid arthritis: current concept and unsolved problems. Front Med (Lausanne). 2022;9:1049875.
Wang Y, Chen S, Du K, Liang C, Wang S, Boadi EO, Li J, Pang X, He J. Chang Y-x, Traditional herbal medicine: therapeutic potential in rheumatoid arthritis. J Ethnopharmacol. 2021;279: 114368.
Article CAS PubMed Google Scholar
Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a register study. Rheumatology. 2016;55(10):1803–11.
Papadopoulou D, Roumelioti F, Tzaferis C, Chouvardas P, Pedersen A-K, Charalampous F, Christodoulou-Vafeiadou E, Ntari L, Karagianni N, Denis MC. Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis. JCI insight. 2023;8:9.
Benjamin O, Goyal A, Lappin SL. Disease-modifying antirheumatic drugs (DMARD). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
Choi J, Fenando A. Sulfasalazine. StatPearls, StatPearls Publishing; 2022.
Ghlichloo I, Gerriets V. Nonsteroidal anti-inflammatory drugs (NSAIDs). StatPearls, StatPearls Publishing; 2023.
Waller DG, Sampson AP. 30 - Rheumatoid arthritis, other inflammatory arthritides and osteoarthritis, in: D.G. Waller, A.P. Sampson (Eds.). Medical Pharmacology and Therapeutics (Fifth Edition). Elsevier; 2018. pp. 373–383.
Cohen S, Tuckwell K, Katsumoto TR, Zhao R, Galanter J, Lee C, Rae J, Toth B, Ramamoorthi N, Hackney JA. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial. Arthritis Rheumatol. 2020;72(9):1435–46.
Article CAS PubMed PubMed Central Google Scholar
Wu H, Yan S, Chen J, Luo X, Li P, Jia X, Dai X, Wang C, Huang Q, Liu L. JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells. Joint Bone Spine. 2016;83(5):525–32.
Article CAS PubMed Google Scholar
Conaghan PG, Nowak M, Du S, Luo Y, Landis J, Pachai C, Fura A, Catlett IM, Grasela DM, Østergaard M. Evaluation of BMS-986142, a reversible Bruton’s tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study. Lancet Rheumatol. 2023;5(5):e263–73.
Article CAS PubMed Google Scholar
Tanaka Y, Genovese MC, Matsushima H, Long-term safety, efficacy, and patient-centered outcomes of filgotinib in the treatment of rheumatoid arthritis: current perspectives, patient preference and adherence 2023;2499–2516.
Peterfy CG, Strand V, Friedman A, Hall S, Mysler E, Durez P, Baraliakos X, Enejosa JV, Shaw T, Li Y. Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program. Rheumatology. 2022;61(8):3246–56.
Article CAS PubMed Google Scholar
Daien C, Krogulec M, Gineste P, Steens J-M, Du Roure LD, Biguenet S, Scherrer D, Santo J, Ehrlich H, Durez P. Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study. Ann Rheum Dis. 2022;81(8):1076–84.
Article CAS PubMed Google Scholar
Yoon S-B, Hong H, Lim H-J, Choi JH, Choi YP, Seo SW, Lee HW, Chae CH, Park W-K, Kim HY. A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway. Acta Pharmaceutica Sinica B. 2023;13(3):1093–109.
Article CAS PubMed Google Scholar
Li J, Li M, Wu D, Zhou J. Leung S-o, Zhang F, SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study. Rheumatology. 2022;61(5):1841–8.
Article CAS PubMed Google Scholar
Gordon D, Kivitz A, Singhal A, Burt D, Bangs MC, Huff EE, Hope HR, Monahan JB. Selective inhibition of the MK2 pathway: data from a phase IIa randomized clinical trial in rheumatoid arthritis. ACR Open Rheumatology. 2023;5(2):63–70.
Article PubMed PubMed Central Google Scholar
Robak E, Robak T. Bruton’s kinase inhibitors for the treatment of immunological diseases: current status and perspectives. J Clin Med. 2022;11(10):2807.
Article CAS PubMed PubMed Central Google Scholar
Montalban X, Wallace D, Genovese MC, et al. Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis. J Neurol Neurosurg Psychiatry. 2023;94(1):1–9.
Abuelazm M, Ghanem A, Mahmoud A, et al. The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis. Clin Rheumatol. 2023;42(6):1503–20.
Article PubMed PubMed Central Google Scholar
Takeuchi T, Chino Y, Kawanishi M, Nakanishi M, Watase H, Mano Y, Sato Y, Uchida S, Tanaka Y. Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials. Arthritis Res Ther. 2023;25(1):60.
Article CAS PubMed PubMed Central Google Scholar
Taylor PC, Weinblatt ME, McInnes IB, Atsumi T, Strand V, Takeuchi T, Bracher M, Brooks D, Davies J, Goode C. Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3). Ann Rheum Dis. 2023;82(12):1527–37.
Article CAS PubMed Google Scholar
Muralidharan S, Njenga M, Garron T, Bondensgaard K, Paolini JF. Preclinical immunopharmacologic assessment of KPL-404, a novel, humanized, non-depleting antagonistic anti-CD40 monoclonal antibody. J Pharmacol Exp Ther. 2022;381(1):12–21.
Article CAS PubMed Google Scholar
Buttgereit F, Aelion J, Rojkovich B, Zubrzycka-Sienkiewicz A, Chen S, Yang Y, Arikan D, D’Cunha R, Pang Y, Kupper H. Efficacy and safety of ABBV-3373, a novel anti–tumor necrosis factor glucocorticoid receptor modulator antibody–drug conjugate, in adults with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a randomized, double-blind, active-controlled proof-of-concept phase IIa trial. Arthritis & Rheumatology. 2023;75(6):879–89.
Deligiannidou G-E, Gougoula V, Bezirtzoglou E, Kontogiorgis C, Constantinides TK. The role of natural products in rheumatoid arthritis: current knowledge of basic in vitro and in vivo research. Antioxidants. 2021;10(4):599.
Article CAS PubMed PubMed Central Google Scholar
Edilova MI, Akram A, Abdul-Sater AA. Innate immunity drives pathogenesis of rheumatoid arthritis. biomed j. 2021;44(2):172–82.
Article CAS PubMed Google Scholar
Laurindo LF, de Maio MC, Barbalho SM, Guiguer EL, Araújo AC, de Alvares GR, Flato UAP, Júnior EB, Detregiachi CRP, dos Santos Haber JF. Organokines in rheumatoid arthritis: a critical review. Int J Mol Sci. 2022;23(11):6193.
Article CAS PubMed PubMed Central Google Scholar
Veselinovic M, Barudzic N, Vuletic M, Zivkovic V, Tomic-Lucic A, Djuric D, Jakovljevic V. Oxidative stress in rheumatoid arthritis patients: relationship to diseases activity. Mol Cell Biochem. 2014;391:225–32.
Comments (0)